NO922182L - Krystallinske oksatiolan-derivater - Google Patents

Krystallinske oksatiolan-derivater

Info

Publication number
NO922182L
NO922182L NO92922182A NO922182A NO922182L NO 922182 L NO922182 L NO 922182L NO 92922182 A NO92922182 A NO 92922182A NO 922182 A NO922182 A NO 922182A NO 922182 L NO922182 L NO 922182L
Authority
NO
Norway
Prior art keywords
oxatatolan
crystallinic
derivatives
oxatatolan derivatives
crystallinic oxatatolan
Prior art date
Application number
NO92922182A
Other languages
English (en)
Other versions
NO301713B1 (no
NO922182D0 (no
Inventor
Paul Ravenscroft
Tony Gordon Roberts
Paul Evans
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO922182(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO922182D0 publication Critical patent/NO922182D0/no
Publication of NO922182L publication Critical patent/NO922182L/no
Publication of NO301713B1 publication Critical patent/NO301713B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Medicinal Preparation (AREA)
NO922182A 1991-06-03 1992-06-02 Krystallinske oksatiolan-derivater NO301713B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds

Publications (3)

Publication Number Publication Date
NO922182D0 NO922182D0 (no) 1992-06-02
NO922182L true NO922182L (no) 1992-12-04
NO301713B1 NO301713B1 (no) 1997-12-01

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
NO922182A NO301713B1 (no) 1991-06-03 1992-06-02 Krystallinske oksatiolan-derivater

Country Status (30)

Country Link
US (1) US5905082A (no)
EP (2) EP1099700A1 (no)
JP (1) JP2851480B2 (no)
KR (1) KR100244008B1 (no)
AP (1) AP300A (no)
AT (1) ATE212630T1 (no)
AU (2) AU656379B2 (no)
BG (1) BG60914B1 (no)
CA (2) CA2070230C (no)
CZ (1) CZ284513B6 (no)
DE (1) DE69232387T2 (no)
DK (1) DK0517145T3 (no)
ES (1) ES2171158T3 (no)
GB (1) GB9111902D0 (no)
GE (1) GEP19991834B (no)
IE (2) IE20020782A1 (no)
IL (1) IL102073A (no)
IS (2) IS1867B (no)
MX (1) MX9202619A (no)
NO (1) NO301713B1 (no)
NZ (1) NZ242981A (no)
OA (1) OA09913A (no)
PT (1) PT517145E (no)
RU (1) RU2102393C1 (no)
SG (1) SG52455A1 (no)
SK (1) SK281249B6 (no)
TW (1) TW254939B (no)
UA (1) UA41265C2 (no)
WO (1) WO1992021676A1 (no)
ZA (1) ZA924007B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
HUP9903249A3 (en) 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CN1503796B (zh) * 2001-03-01 2012-07-04 三角药品公司 顺-ftc的多晶型物及其它晶型
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
ATE361059T1 (de) * 2002-11-08 2007-05-15 Glaxo Group Ltd Antivirale zusammensetzungen
WO2004064846A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2006053134A2 (en) * 2004-11-10 2006-05-18 Novartis Vaccines And Diagnostics Inc. Deamidated interferon-beta
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
DE602007009957D1 (de) * 2006-04-18 2010-12-02 Lupin Ltd Neue kristalline form von lamivudin
US20090068267A1 (en) * 2007-09-06 2009-03-12 Combino Pharm, S.L. Novel Pharmaceutical Compositions
WO2009037538A2 (en) * 2007-09-17 2009-03-26 Aurobindo Pharma Ltd Process for the preparation of lamivudine form i
US20100311970A1 (en) * 2007-11-29 2010-12-09 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
AU2008331168A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Crystalline form I of lamivudine and its preparation
CN101918416A (zh) * 2007-11-29 2010-12-15 兰贝克赛实验室有限公司 制备取代的1,3-氧硫杂环戊烷,尤其是拉米夫定的方法和中间体
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
WO2010023676A2 (en) * 2008-09-01 2010-03-04 Hetero Research Foundation Process for preparing lamivudine polymorph form
EP2350065A1 (en) * 2008-11-12 2011-08-03 Lupin Ltd. A novel polymorph of emtricitabine and a process for preparing of the same
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
EP2435052B1 (en) * 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
WO2011007367A1 (en) 2009-07-15 2011-01-20 Lupin Limited An improved process for preparation of efavirenz
WO2011045815A2 (en) 2009-10-14 2011-04-21 Matrix Laboratories Ltd. Process for the preparation of lamivudine and novel salts in the manufacture thereof
MY188334A (en) 2010-01-27 2021-11-30 Viiv Healthcare Co Antiviral therapy
US20120295930A1 (en) * 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
AU2011215878A1 (en) * 2010-02-12 2012-08-09 Merck Sharp & Dohme Corp. Preparation of lamivudine Form I
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
WO2013021290A1 (en) 2011-08-05 2013-02-14 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
JPH04358486A (ja) * 1991-06-04 1992-12-11 Toshiba Corp 高能率符号化信号処理装置

Also Published As

Publication number Publication date
CZ261293A3 (en) 1994-04-13
IS4268A (is) 1995-02-27
IS3873A (is) 1992-12-04
SG52455A1 (en) 1998-09-28
IS1867B (is) 2003-05-02
NZ242981A (en) 1994-04-27
RU2102393C1 (ru) 1998-01-20
NO301713B1 (no) 1997-12-01
AU656379B2 (en) 1995-02-02
EP1099700A1 (en) 2001-05-16
ES2171158T3 (es) 2002-09-01
CA2311988C (en) 2005-11-15
EP0517145B1 (en) 2002-01-30
IE921780A1 (en) 1992-12-16
SK281249B6 (sk) 2001-01-18
CA2070230C (en) 2004-08-03
BG98254A (bg) 1994-07-29
US5905082A (en) 1999-05-18
OA09913A (en) 1994-09-15
HK1009599A1 (en) 1999-06-04
AU1736192A (en) 1993-03-11
PT517145E (pt) 2002-07-31
GB9111902D0 (en) 1991-07-24
DK0517145T3 (da) 2002-05-06
CA2070230A1 (en) 1992-12-04
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
WO1992021676A1 (en) 1992-12-10
MX9202619A (es) 1992-12-01
KR930000511A (ko) 1993-01-15
BG60914B1 (bg) 1996-06-28
NO922182D0 (no) 1992-06-02
UA41265C2 (uk) 2001-09-17
TW254939B (no) 1995-08-21
CA2311988A1 (en) 1992-12-04
AP300A (en) 1994-01-20
DE69232387D1 (de) 2002-03-14
CZ284513B6 (cs) 1998-12-16
AU1881092A (en) 1993-01-08
JP2851480B2 (ja) 1999-01-27
IL102073A (en) 1996-05-14
SK125793A3 (en) 1994-11-09
IE20020782A1 (en) 2003-04-02
KR100244008B1 (ko) 2000-03-02
IL102073A0 (en) 1993-01-14
ZA924007B (en) 1993-04-28
EP0517145A1 (en) 1992-12-09
JPH06211848A (ja) 1994-08-02
GEP19991834B (en) 1999-11-05
DE69232387T2 (de) 2002-09-26

Similar Documents

Publication Publication Date Title
DE69208877D1 (de) Chinuclidinderivate
FI924160A7 (fi) Benzanilidderivat
FI935726A7 (fi) Atsanorbornaanijohdannaisia
FI924159L (fi) Benzanilidderivat
NO922182L (no) Krystallinske oksatiolan-derivater
FI930262L (fi) Kinuklidinderivat
DE69119329D1 (de) Actinonin-Derivate
FI925523A0 (fi) Hydroxi- och alkoxipyridinderivat
FI925422L (fi) Indolopyrrolokarbazolderivat
DE69125099D1 (de) Indolderivate
FI913045A7 (fi) Heterosykleenijohdannaisia
FI921262L (fi) 4-aryltiazol- eller 4-arylimidazolderivat
FI930878L (fi) A-substituerade tryptofan-dipeptoidderivat
FI923726L (fi) Sulfaterade glykosaminoglykanoidderivat
FI925763A0 (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
FI922347A7 (fi) Atsaoksindolijohdannaiset
ATE144765T1 (de) Hiv-hemmende benzenacetamidderivate
FI930345L (fi) Foerfarande foer framstaellning av renat akrylamidosulfonsyramonomerderivat
ATE171449T1 (de) Oxadolderivate
FI930109L (fi) 4-alkyl-imidazolderivat
FI935243L (fi) Pyridonkarboxylsyraderivat
DK0472733T3 (da) Phenantrenderivater
FI912598A7 (fi) Diokso-tetrahydrokinoliinijohdannaisia
FI912759A7 (fi) Pyridinyylipiperatsiinijohdannaisia
FI920394A7 (fi) 3-kinuklidiinijohdannaiset

Legal Events

Date Code Title Description
MK1K Patent expired